13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001622627
Total reported value
$269.2M
$269.2M
37 檔
31.7%
At the close of Q2 2025, Rosalind Advisors, Inc. disclosed equity holdings valued at approximately $269.2M, spread across 37 reported holdings.
During Q2 2025, Rosalind Advisors, Inc.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including DCTH, FENC, CYTK) accounted for 31.7% of total reported equity market value during Q2 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DCTH | Delcath Systems Inc | Stock-Other | 15.65% | +3.13% | +13.79% | |
| 2 | FENC | Fennec Pharmaceuticals Inc | Stock-Other | 8.05% | +5.54% | +14.74% | |
| 3 | CYTK | Cytokinetics Inc | Stock-Healthcare | 6.27% | — | — | |
| 4 | OCUL | Ocular Therapeutix Inc | Stock-Other | 5.36% | — | — | |
| 5 | IDYA | Ideaya Biosciences Inc | Stock-Other | 5.09% | — | -26.98% | |
| 6 | XERS | Xeris Biopharma Holdings Inc | Stock-Other | 4.77% | +1.03% | -13.64% | |
| 7 | VRDN | Viridian Therapeutics Inc | Stock-Other | 4.64% | -1.97% | EXIT | |
| 8 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 4.48% | — | — | |
| 9 | VSTM | Verastem Inc | Stock-Other | 4.02% | +1.11% | -22.72% | |
| 10 | REPL | Replimune Group Inc | Stock-Other | 3.96% | — | +5.88% | |
| 11 | ✓ | Mediwound LTD | Stock-Other | 3.74% | -0.76% | -19.69% | |
| 12 | MYO | Myomo Inc | Stock-Other | 3.68% | +0.37% | +33.00% | |
| 13 | RZLT | Rezolute Inc | Stock-Other | 3.68% | — | — | |
| 14 | URGN | UroGen Pharma Ltd. | Stock-Other | 3.52% | — | -42.91% | |
| 15 | HELP | Cybin Inc | Stock-Other | 3.23% | +1.85% | — | |
| 16 | SVRA | Savara Inc | Stock-Other | 2.87% | +0.24% | — | |
| 17 | NSPR | Inspiremd Inc | Stock-Other | 2.46% | -1.54% | +0.62% | |
| 18 | CGON | Cg Oncology Inc | Stock-Other | 2.38% | -2.72% | EXIT | |
| 19 | PROF | Profound Medical CORP | Stock-Other | 1.94% | -0.11% | — | |
| 20 | PHVS | Pharvaris N.V. | Stock-Other | 1.87% | — | — | |
| 21 | ✓ | Polypid LTD | Stock-Other | 1.63% | -0.32% | -4.18% | |
| 22 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 1.29% | — | — | |
| 23 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.85% | — | -48.09% | |
| 24 | ✓ | Inmune Bio Inc | Stock-Other | 0.84% | — | — | |
| 25 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.78% | — | -51.05% | |
| 26 | CMPS | Compass Pathways PLC | Stock-Other | 0.64% | — | -41.38% | |
| 27 | TLPH | Talphera Inc | Stock-Other | 0.44% | +0.97% | — | |
| 28 | BFRI | Biofrontera Inc | Stock-Other | 0.33% | +0.07% | +51.53% | |
| 29 | ✓ | Urogen Pharma LTD | Stock-Other | 0.28% | — | — | |
| 30 | KURA | Kura Oncology Inc | Stock-Other | 0.27% | +0.08% | — | |
| 31 | ✓ | Spdr Series Trust | Stock-Other | 0.25% | +0.01% | NEW | |
| 32 | ✓ | Replimune Group Inc | Stock-Other | 0.24% | -1.10% | EXIT | |
| 33 | ✓ | Spdr S&P 500 Etf Tr Put Option | ETF-Large Cap & Growth | 0.21% | -0.39% | EXIT | |
| 34 | ✓ | Atyr Pharma Inc | Stock-Other | 0.13% | — | — | |
| 35 | OVID | Ovid Therapeutics Inc | Stock-Other | 0.08% | +0.12% | — | |
| 36 | ✓ | Ideaya Biosciences Inc | Stock-Other | 0.03% | — | — | |
| 37 | ✓ | Crinetics Pharmaceuticals In | Stock-Other | 0.03% | — | — |
According to official SEC Form 13F filings, Rosalind Advisors, Inc. reported a total U.S. public equity portfolio value of $269.2M across 37 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
During Q2 2025, Rosalind Advisors, Inc.'s top holdings by market value included DCTH (15.7%)、FENC (8.1%)、CYTK (6.3%). The largest single position, DCTH, represented 15.7% of total portfolio value.
In Q2 2025, Rosalind Advisors, Inc. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.